QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN received FDA clearance for its QIAstat-Dx BCID GN Plus AMR Panel, completing the U.S. QIAstat-Dx bloodstream infection portfolio. The new panel detects 13 gram-negative bacterial targets and 18 antibiotic resistance markers in about one hour, complementing the recently cleared gram-positive/fungal panel; together they cover 33 pathogen targets and 28 resistance markers. The clearance expands QIAstat-Dx's U.S.
Key figures
- Drug Name
- QIAstat-Dx BCID GN Plus AMR Panel
- Sepsis deaths
- at least 350,000
- Time to result
- about one hour
- Gram negative targets
- 13
- Qiastat dx placements
- more than 5,200 cumulative as of end of 2025
- Sepsis cases us annually
- 1.7 million
- Combined pathogen targets
- 33
- Combined resistance markers
- 28
- Gram negative resistance markers
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.